§ 522.778  Doxycycline hyclate.

(a) Specifications.  Doxycycline hyclate solution contains 8.5 percent doxycycline activity. A syringe of N-methyl-2-pyrrolidone and poly(DL-lactide) mixed with a syringe of doxycycline produces 0.5 milliliter of solution.

(b) Sponsor.  See 000009 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Dogs—(i) Amount.  Apply subgingivally to periodontal pocket(s) of affected teeth.

(ii) Indications for use.  For treatment and control of periodontal disease.

(iii) Limitations.  Do not use in dogs less than 1-year old. Use of tetracyclines during tooth development has been associated with permanent discoloration of teeth. Do not use in pregnant bitches. Use in breeding dogs has not been evaluated. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.800  Droperidol and fentanyl citrate injection.

(a) Specifications.  Droperidol and fentanyl citrate injection is a sterile solution containing 20 milligrams of droperidol and 0.4 milligram of fentanyl citrate per cubic centimeter.

(b) Sponsor.  See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use.  (1) It is used in dogs as an analgesic and tranquilizer and for general anesthesia.

(2) It is administered as follows:

(i) For analgesia and tranquilization administer according to response desired, as follows:

(a) Intramuscularly at the rate of 1 cubic centimeter per 15 to 20 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight, or

(b) Intravenously at the rate of 1 cubic centimeter per 25 to 60 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight.

(2) For general anesthesia administer according to response desired, as follows:

(a) Intramuscularly at the rate of 1 cubic centimeter per 40 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight and followed in 10 minutes by an intravenous administration of sodium pentobarbital at the rate of 3 milligrams per pound of body weight, or

(b) Intravenously at the rate of 1 cubic centimeter per 25 to 60 pounds of body weight in conjunction with atropine sulfate administered at the rate of 0.02 milligram per pound of body weight and followed within 15 seconds by an intravenous administration of sodium pentobarbital at the rate of 3 milligrams per pound of body weight.